US EditionAmsterdam’s Avidicure exits stealth mode with €43.8M to develop new antibody therapies - Silicon Canals
Summary by Silicon Canals
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Amsterdam’s Avidicure exits stealth mode with €43.8M to develop new antibody therapies - Silicon Canals
Based out of Amsterdam, Avidicure, a biotechnology company, announced its launch with $50M (approximately €43.8M) in a seed financing round led by EQT Life Sciences. Additional investors, including Kurma Partners, BioGeneration Ventures, BOM, Curie Capital, and V-Bio Ventures, also participated in the round. Avidicure: Developing multifunctional antibody modality to treat cancer Led by Arthur Lahr, Avidicure is developing dual agonistic, multi…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
